ASH 2023 | Developments in PV and ET discussed at ASH 2023
Douglas Tremblay, MD, Icahn School of Medicine at Mount Sinai, New York, NY, comments on the recent lack of evolution in the management of polycythemia vera (PV) and essential thrombocythemia (ET), two chronic myeloproliferative neoplasms (MPNs). While most treatments aim to reduce the risk of thrombosis, the leading cause of morbidity and mortality, this does not increase the knowledge of which patients should be treated with cytoreductive therapies. Research has suggested that interferon therapies may reduce the mutational burden and improve event-free survival (EFS) in PV, while both PV and ET may be controlled by novel therapies such as rusfertide, a hepcidin mimetic, which can maintain hematocrit levels and reduce symptoms. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
